DK3658552T3 - Fremgangsmåde til fremstilling af n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamid ved reaktion af den tilsvarende amin med et 3-halogen-propionylchlorid - Google Patents

Fremgangsmåde til fremstilling af n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamid ved reaktion af den tilsvarende amin med et 3-halogen-propionylchlorid Download PDF

Info

Publication number
DK3658552T3
DK3658552T3 DK18837360.9T DK18837360T DK3658552T3 DK 3658552 T3 DK3658552 T3 DK 3658552T3 DK 18837360 T DK18837360 T DK 18837360T DK 3658552 T3 DK3658552 T3 DK 3658552T3
Authority
DK
Denmark
Prior art keywords
morpholinophenyl
pyrazol
pyrimidin
acrylamide
dimethylamino
Prior art date
Application number
DK18837360.9T
Other languages
English (en)
Inventor
Ja-Heouk Khoo
Jong-Chul Lim
Seong-Ran Lee
Hyun Ju
Woo-Seob Shin
Dae-Gyu Park
su-min Park
Yoon-Ah Hwang
Sang-Ho Oh
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65040211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3658552(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Application granted granted Critical
Publication of DK3658552T3 publication Critical patent/DK3658552T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/22Tin compounds
    • C07F7/2284Compounds with one or more Sn-N linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
DK18837360.9T 2017-07-28 2018-07-25 Fremgangsmåde til fremstilling af n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamid ved reaktion af den tilsvarende amin med et 3-halogen-propionylchlorid DK3658552T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170096212 2017-07-28
PCT/KR2018/008379 WO2019022485A1 (en) 2017-07-28 2018-07-25 IMPROVED PROCESS FOR THE PREPARATION OF AMINOPYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
DK3658552T3 true DK3658552T3 (da) 2023-11-20

Family

ID=65040211

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18837360.9T DK3658552T3 (da) 2017-07-28 2018-07-25 Fremgangsmåde til fremstilling af n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamid ved reaktion af den tilsvarende amin med et 3-halogen-propionylchlorid

Country Status (31)

Country Link
US (4) US10889578B2 (da)
EP (1) EP3658552B1 (da)
JP (2) JP7228562B2 (da)
KR (1) KR20190013553A (da)
CN (2) CN111315742B (da)
AU (2) AU2018308038B2 (da)
BR (1) BR112020001278A2 (da)
CA (1) CA3070069C (da)
CO (1) CO2020000374A2 (da)
DK (1) DK3658552T3 (da)
EA (1) EA202090383A1 (da)
ES (1) ES2962961T3 (da)
FI (1) FI3658552T3 (da)
HR (1) HRP20231191T1 (da)
HU (1) HUE063533T2 (da)
IL (2) IL271973B (da)
LT (1) LT3658552T (da)
MA (1) MA49700B1 (da)
MD (1) MD3658552T2 (da)
MX (1) MX2022008743A (da)
NZ (1) NZ761156A (da)
PH (1) PH12020500059A1 (da)
PL (1) PL3658552T3 (da)
PT (1) PT3658552T (da)
RS (1) RS64654B1 (da)
SA (1) SA520411112B1 (da)
SG (1) SG11201913517UA (da)
SI (1) SI3658552T1 (da)
UA (1) UA125317C2 (da)
WO (1) WO2019022485A1 (da)
ZA (1) ZA202001250B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64654B1 (sr) * 2017-07-28 2023-10-31 Yuhan Corp Proces za pripremu n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2- morfolinofenil)akrilamida reakcijom odgovarajućeg amina sa 3-halo-propionil hloridom
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US6821988B2 (en) 2001-11-27 2004-11-23 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Jak 저해제들과 bcr-abl, flt-3, fak 또는raf 키나제 저해제들 중 하나 이상의 조합물
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
ES2711249T3 (es) 2008-06-27 2019-04-30 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
CA2777762A1 (en) 2009-10-12 2011-04-21 Myrexis, Inc. Amino - pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilon
US8629132B2 (en) 2009-11-13 2014-01-14 Genosco Kinase inhibitors
CA2782684C (en) 2009-12-04 2018-09-04 Mustapha Haddach Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
EP2624696B1 (en) 2010-10-06 2016-12-21 Glaxosmithkline LLC Benzimidazole derivatives as pi3 kinase inhibitors
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA3027814A1 (en) 2010-12-13 2012-06-21 Array Biopharma Inc. Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as intermediates for type iii receptor tyrosine kinase inhibitors
PL3686194T3 (pl) * 2011-07-27 2022-01-17 Astrazeneca Ab Związki 2-(2,4,5-podstawione-anilino)pirymidynowe
TW201332988A (zh) 2011-12-23 2013-08-16 Millennium Pharm Inc 雜芳基化合物及其用途
RU2705577C2 (ru) 2011-12-30 2019-11-08 Ханми Фарм. Ко., Лтд. ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ
CN104860891B (zh) 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物
WO2015175632A1 (en) 2014-05-13 2015-11-19 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
WO2015188777A1 (en) 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
MX2017003181A (es) * 2014-10-13 2017-07-20 Yuhan Corp Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico.
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR102263A1 (es) 2015-10-14 2017-02-15 Yuhan Corp Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante
DE102017212159A1 (de) 2017-07-14 2019-01-17 Krones Aktiengesellschaft Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden
SG11201913556SA (en) 2017-07-28 2020-02-27 Yuhan Corp Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
RS64654B1 (sr) 2017-07-28 2023-10-31 Yuhan Corp Proces za pripremu n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2- morfolinofenil)akrilamida reakcijom odgovarajućeg amina sa 3-halo-propionil hloridom
CN108826170A (zh) 2018-06-26 2018-11-16 深圳市远润欣电子有限公司 局部全般照明的模式、控制方法及台灯

Also Published As

Publication number Publication date
CO2020000374A2 (es) 2020-05-05
PH12020500059A1 (en) 2020-09-28
PL3658552T3 (pl) 2024-02-19
MA49700A (fr) 2021-03-17
AU2018308038B2 (en) 2022-02-03
AU2018308038A1 (en) 2020-01-30
AU2022202936A1 (en) 2022-05-26
ZA202001250B (en) 2023-04-26
HRP20231191T1 (hr) 2024-02-02
IL292429A (en) 2022-06-01
IL271973A (en) 2020-02-27
US20210269427A1 (en) 2021-09-02
US11286253B2 (en) 2022-03-29
HUE063533T2 (hu) 2024-01-28
ES2962961T3 (es) 2024-03-22
US20220281861A1 (en) 2022-09-08
BR112020001278A2 (pt) 2020-07-21
KR20190013553A (ko) 2019-02-11
MA49700B1 (fr) 2023-09-27
NZ761156A (en) 2024-01-26
SI3658552T1 (sl) 2023-11-30
IL292429B2 (en) 2023-09-01
JP7228562B2 (ja) 2023-02-24
FI3658552T3 (fi) 2023-11-16
JP2023027091A (ja) 2023-03-01
CN116987112A (zh) 2023-11-03
CA3070069C (en) 2024-02-20
UA125317C2 (uk) 2022-02-16
PT3658552T (pt) 2023-11-03
LT3658552T (lt) 2023-11-27
RS64654B1 (sr) 2023-10-31
EP3658552B1 (en) 2023-09-13
US11708362B2 (en) 2023-07-25
CN111315742A (zh) 2020-06-19
IL292429B1 (en) 2023-05-01
US20230312545A1 (en) 2023-10-05
EP3658552A4 (en) 2021-06-23
MD3658552T2 (ro) 2024-02-29
IL271973B (en) 2022-08-01
CA3070069A1 (en) 2019-01-31
SA520411112B1 (ar) 2022-02-21
SG11201913517UA (en) 2020-02-27
WO2019022485A1 (en) 2019-01-31
EP3658552A1 (en) 2020-06-03
US20200165236A1 (en) 2020-05-28
AU2022202936B2 (en) 2023-04-27
CN111315742B (zh) 2023-09-01
US10889578B2 (en) 2021-01-12
JP2020528440A (ja) 2020-09-24
EA202090383A1 (ru) 2020-06-15
MX2022008743A (es) 2023-02-02

Similar Documents

Publication Publication Date Title
DK3658552T3 (da) Fremgangsmåde til fremstilling af n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamid ved reaktion af den tilsvarende amin med et 3-halogen-propionylchlorid
DK3606909T3 (da) Natriumsalt af n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazol-3-sulfonamid
PH12018502136A1 (en) Heterocyclic amides useful as protein modulators
DK3555070T3 (da) Aminsubstituerede, heterocykliske forbindelser som ehmt2-hæmmere og fremgangsmåder til anvendelse deraf
EA201692356A1 (ru) Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида
EA201591506A1 (ru) Гетероциклические амины в качестве ингибиторов киназы
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
PE20161427A1 (es) Inhibidores heteroarilo de syk
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201790785A1 (ru) Производные тетрагидроизохинолина
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
MA43251A (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
DK3472165T3 (da) N-(substituererede-phenyl)-sulfonamidderivater som kinasehæmmere
MA56021A (fr) Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
DK2358691T3 (da) Fremgangsmåde til fremstilling af piperazinforbindelser og hydrochloridsalte deraf
IL254132B (en) A solid preparation of N-(4-(1(2,6-difluorobenzyl)-5-))dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxy-1,2,3 4-tetrahydrothiano[2,3-d]pyrimidine-6-yl)phenyl)-n-methoxyurea or its salt
MA51619A (fr) Inhibiteurs de la protéine kinase dépendante de l'adn
EA201892264A1 (ru) Производные тетрагидроизохинолина
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
MX2017013248A (es) Compuesto del inhibidor fgfr4 cristalino y usos del mismo.
PH12015500795B1 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
SG11201911859QA (en) Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
EA201391744A1 (ru) Производные 2-амино-3-(имидазол-2-ил)-пиридин-4-она и их применение в качестве ингибиторов киназы рецептора vegf
IL263619A (en) Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof